Multi-Agent Based Automation of Pathology Slide and Genomic Data Correlation

Manual correlation of histopathology slides with genomic variant reports is a bottleneck, requiring pathologists and oncologists to toggle between PACS, LIMS, and literature databases. A custom agentic workflow automates this synthesis, ingesting WSI and genomic PDFs to produce a unified, evidence-backed report in minutes. This compresses case preparation from 4-8 hours to under 30 minutes, freeing specialist time for higher-value decision-making and increasing tumor board throughput by 40-60%.

Manual research risks missing subtle biomarker-therapy associations buried in dense literature. An automated workflow uses a RAG-powered knowledge agent to query the latest clinical trials, guidelines, and drug labels against the patient's specific genomic and histologic profile. This systematic approach reduces oversight, improving the accuracy of targeted therapy recommendations and identifying viable trial candidates that manual screening might miss, potentially increasing trial enrollment rates by 15-25%.

Interpretation consistency varies across pathologists, especially for rare variants. The workflow embeds institutional guidelines and consensus rules into agent logic, providing a standardized, evidence-anchored second read. It acts as a force multiplier for junior pathologists or centers with sub-specialty gaps, offering explainable reasoning for each correlation. This reduces diagnostic variability, strengthens confidence in complex cases, and creates a scalable training and quality assurance layer.

Beyond single-case automation, the workflow builds a continuously learning, de-identified knowledge graph linking histologic patterns, genomic variants, and clinical outcomes. This becomes a proprietary institutional asset for retrospective research and model refinement. The architecture is built for HIPAA compliance from the ground up, with data anonymization agents, strict access controls, and full audit trails for every automated decision and data access, ensuring regulatory defensibility.

The high labor cost of manual correlation directly impacts the economics of precision oncology programs. Automating this repetitive, research-intensive task converts fixed labor cost into scalable compute cost. For an academic center handling 500+ complex molecular cases annually, the workflow can reduce associated FTE requirements by 1-2, yielding a direct operational savings of $150k-$300k annually while improving case capacity without adding staff.

The aggregated, correlated data generated by the workflow fuels translational research. Bioinformaticians and researchers gain programmatic access to a cohort discovery engine that can find patients with specific histologic-genomic signatures in seconds. This accelerates retrospective studies, biomarker discovery, and the development of new internal testing protocols, turning operational workflow output into a competitive research advantage.

This agent orchestrates the ingestion of whole-slide image (WSI) files from the PACS/VNA, runs pre-trained deep learning models for tumor segmentation, grading, and biomarker quantification (e.g., PD-L1, HER2), and extracts structured feature vectors. It handles gigapixel tiling, manages GPU inference queues, and outputs a standardized JSON payload with confidence scores and region-of-interest coordinates for downstream correlation.

A specialized NLP agent parses unstructured next-generation sequencing (NGS) reports from LIS systems like Epic Beaker or LabVantage. It extracts variants (SNVs, CNVs, fusions), tumor mutational burden (TMB), microsatellite instability (MSI) status, and therapeutic implications using a fine-tuned LLM with grounding in clinical genetics ontologies (e.g., ClinVar, OncoKB). It normalizes data into a structured variant call format (VCF) schema for knowledge graph ingestion.

The core reasoning layer. This component maintains a continuously updated knowledge graph linking genomic variants to FDA-approved therapies, clinical trial eligibility criteria, prognostic associations, and resistance mechanisms. Upon receiving structured inputs from the WSI and NLP agents, it performs a subgraph query to find evidence-based connections, generating ranked hypotheses (e.g., 'BRCA1 mutation + high tumor grade suggests PARP inhibitor eligibility'). Built with graph databases like Neo4j and RAG over curated literature.

A LangGraph or Temporal-based orchestrator that sequences agent execution, manages state, and enforces HIPAA-compliant data flows. It introduces mandatory approval gates: all agent-generated correlations are presented in a secure, audit-ready dashboard for pathologist review before being finalized. The controller logs all decisions, rationale, and overrides, creating a defensible chain of custody for the diagnostic support process.

This is the production-grade integration component that connects the custom workflow to hospital IT ecosystems. It provides HL7/FHIR APIs for bidirectional data exchange with the EHR (Epic, Cerner), pushes finalized correlation summaries and trial matches into the molecular tumor board module, and retrieves patient context. It also handles DICOMweb communication with the PACS for WSI retrieval and result annotation storage.

Upside: Reduces manual research from 2-4 hours to ~15 minutes per complex oncology case, accelerating tumor board preparation and potentially improving time-to-therapy initiation. Implementation: A 12-week pilot for a single cancer type (e.g., NSCLC) is typical, starting with a sandboxed environment using synthetic data, progressing to a live shadow mode running parallel to existing workflows, and culminating in a phased rollout with strict change management and clinician training.

The workflow ingests high-resolution pathology slide images (e.g., .svs, .ndpi) directly from the hospital's PACS or dedicated digital pathology storage. Agents must handle asynchronous, large-file transfers (often 1-5GB per slide) and trigger AI inference engines for tumor segmentation, grading, and biomarker quantification (e.g., PD-L1, HER2). Integration requires DICOMweb or vendor-specific APIs, with caching strategies to manage latency for downstream genomic correlation agents.

Structured variant call format (VCF) files and unstructured PDF reports from next-generation sequencing (NGS) labs are ingested via HL7 or direct API connections to the Laboratory Information System (LIMS). NLP agents parse complex, non-standardized report text to extract variants, allele frequencies, and therapeutic significance. This pipeline must be version-controlled to track changes in assay panels and reporting formats, ensuring correlation logic remains accurate.

A central, HIPAA-compliant knowledge graph stores fused patient entities (slide ID, variant ID, patient MRN) and their relationships. It is enriched via a Retrieval-Augmented Generation (RAG) pipeline that continuously indexes clinical guidelines (NCCN, ASCO), drug labels, and trial eligibility criteria from PubMed and ClinicalTrials.gov. Correlation agents query this graph to find evidence linking histopathological phenotypes (from WSI AI) with genomic alterations, powering therapy and trial match suggestions.

The final correlation output—a synthesized report with ranked therapeutic hypotheses—must be injected into the clinician's workflow. This requires a two-way integration with the EHR (e.g., Epic, Cerner) via FHIR APIs. The system creates a pre-populated case packet in the MTB module, triggers notifications to assigned pathologists and oncologists, and writes back structured findings (e.g., therapy matches with confidence scores) as discrete data for future analytics and treatment planning.

A central orchestrator (built on frameworks like LangGraph or Temporal) manages the stateful workflow: triggering the WSI agent upon slide availability, waiting for genomic data, launching the correlation agent, and routing low-confidence results for human-in-the-loop review. This layer enforces governance: logging all agent decisions, managing API rate limits to clinical systems, and providing a unified observability dashboard for audit trails, performance metrics, and exception handling.

The entire workflow operates within a zero-trust architecture. All data in transit and at rest is encrypted (HIPAA-compliant). Access is controlled via integration with hospital identity providers (e.g., Active Directory). Agents operate with least-privilege service accounts. The system must support data sovereignty for multi-center trials and include automated PHI detection and masking for any data used in non-production model retraining. Compliance reporting for CAP/CLIA and 21 CFR Part 11 (if applicable) is built-in.